SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Anderson Mats)
 

Sökning: WFRF:(Anderson Mats) > (2010-2014) > Population-Based St...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005389naa a2200577 4500
001oai:DiVA.org:uu-154544
003SwePub
008110607s2011 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:130189d7-56cf-4c13-a1fc-08a5d1bd7a00
009oai:prod.swepub.kib.ki.se:122594872
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1545442 URI
0247 a https://doi.org/10.1200/JCO.2010.29.12782 DOI
0247 a https://lup.lub.lu.se/record/19372442 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1225948722 URI
040 a (SwePub)uud (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Olofsson, Sven-Erik4 aut
2451 0a Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor :b A Report From the Swedish-Norwegian Testicular Cancer Group
264 1c 2011
338 a print2 rdacarrier
520 a Purpose From 1995 to 2003, 603 adult patients from Sweden and Norway with metastatic testicular nonseminomatous germ cell tumor (NSGCT) were included prospectively in a population-based protocol with strict guidelines for staging, treatment, and follow-up. Patients with extragonadal primary tumor or previous treatment for contralateral testicular tumor were excluded. The basic strategy was to individualize treatment according to initial tumor marker response. Methods Initial treatment for all patients was two courses of standard bleomycin, etoposide, and cisplatin (BEP), with tumor markers analyzed weekly. Good response was defined as a half-life (t(1/2)) for alpha-fetoprotein (AFP) of <= 7 days and/or for beta-human chorionic gonadotropin (beta-HCG) of <= 3 days. Patients with prolonged marker t(1/2) (ie, poor response) received intensification with addition of ifosfamide (BEP-if/PEI) in step 1. If poor response continued, the treatment was intensified with high-dose chemotherapy with stem-cell rescue as step 2. Results Overall, 99% of all patients with metastatic testicular NSGCT in the population were included in the protocol. Median follow-up was 8.2 years. Seventy-seven percent of the patients were treated with BEP alone; 18% received intensification step 1%, and 5% received intensification step 2. Grouped according to International Germ Cell Consensus Classification, 10-year overall survival was 94.7% in good-prognosis patients, 90.0% in intermediate-prognosis patients, and 67.4% in poor-prognosis patients. Conclusion With detailed treatment protocols and a dedicated collaborative group of specialists, treatment results comparable to those reported from large single institutions can be achieved at national level. With the treatment principles used in Swedish-Norwegian Testicular Cancer Group study SWENOTECA IV, the survival of intermediate-prognosis patients is remarkable and close to that of good-prognosis patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a MEDICINE
653 a MEDICIN
7001 a Tandstad, Torgrim4 aut
7001 a Jerkeman, Matsu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mje
7001 a Dahl, Olav4 aut
7001 a Ståhl, Olofu Lund University,Lunds universitet,Reproduktionsmedicin, Malmö,Forskargrupper vid Lunds universitet,Reproductive medicine, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)kir-ost
7001 a Klepp, Olbjörn4 aut
7001 a Bremnes, Roy M.4 aut
7001 a Cohn-Cedermark, Gabriellau Karolinska Institutet4 aut
7001 a Langberg, Carl W.4 aut
7001 a Laurell, Annau Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)annajohn
7001 a Solberg, Arne4 aut
7001 a Stierner, Ulrika4 aut
7001 a Wahlqvist, Rolf4 aut
7001 a Wijkström, Hans4 aut
7001 a Anderson, Haraldu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-han
7001 a Cavallin-Ståhl, Evau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ecs
7102 a Bröstcancer-genetikb Sektion I4 org
7730 t Journal of Clinical Oncologyg 29:15, s. 2032-2039q 29:15<2032-2039x 0732-183Xx 1527-7755
8564 u http://www.ncbi.nlm.nih.gov/pubmed/21482994?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1200/JCO.2010.29.1278y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-154544
8564 8u https://doi.org/10.1200/JCO.2010.29.1278
8564 8u https://lup.lub.lu.se/record/1937244
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:122594872

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy